论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
LncRNA LEF1-AS1 通过与 miR-1285-3p 相互作用促进卵巢癌发展
Authors Zhang Y, Ruan F
Received 17 August 2019
Accepted for publication 30 November 2019
Published 30 January 2020 Volume 2020:12 Pages 687—694
DOI https://doi.org/10.2147/CMAR.S227652
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Dr Ahmet Emre Eskazan
Background: Growing evidence indicates that long noncoding RNA (lncRNA) is a group of important regulator in cancer development. However, the correlation between lncRNA and ovarian cancer remains elusive. Here, we aimed to investigate the roles of LEF1-AS1 in ovarian cancer progression.
Methods: LEF1-AS1 expression was analyzed by quantitative real-time polymerase chain reaction (qRT-PCR). Survival rate was analyzed by Kaplan-Meier method. Cell Counting Kit-8 (CCK8) and colony formation assays were used for proliferation analysis. Transwell assay was utilized for analyses of migration and invasion. Luciferase reporter assay was performed to test the interaction between LEF1-AS1 and miR-1285-3p.
Results: We showed that LEF1-AS1 expression was upregulated in ovarian cancer tissues compared with normal tissues. Besides, LEF1-AS1 level was positively correlated with lymph node metastasis and advanced stage. Enhanced expression of LEF1-AS1 may predict a poor prognosis. Moreover, LEF1-AS1 knockdown suppressed ovarian cancer cell proliferation, migration and invasion. Mechanistically, LEF1-AS1 exerted its oncogenic functions through interacting with miR-1285-3p to inhibit miRNA activity. Rescue assay validated that miR-1285-3p inhibitors abrogated LEF1-AS1-silencer-caused suppression of ovarian cancer progression.
Conclusion: Our study revealed that LEF1-AS1 acts as a vital regulation in ovarian cancer progression.
Keywords: ovarian cancer, LEF1-AS1, miR-1285-3p, progression
